VBCC Perspectives

Patient-Centric Cancer Care

Rick Lee

July 2015, Vol 6, No 6 - VBCC Perspectives

Rising to a level of equal status with cancer providers is a tall order for patients with cancer, yet it is precisely the intent of the Meaningful Use Stage 3 proposed standards that are set to take effect in 2018 (ie, patient-reported outcomes), as well as the value-based care initiatives. Providers need to drop their resistance and contemplate the following benefits of patient centricity. [ Read More ]

The ASCO Value Framework: To What End?

Edward C. Li, PharmD, MPH, BCOP

July 2015, Vol 6, No 6 - VBCC Perspectives

In the modern era of increasing healthcare costs, and with prescription drug expenditures forecasted to increase by 7% to 9% in the next year, a focused discussion on the value proposition of cancer care is warranted. The American Society of Clinical Oncology (ASCO) Value in Cancer Care Task Force should be commended for igniting the conversation about the value of chemotherapy regimens. We live in a society with a limited amount of resources, and, therefore, resources such as treatment options must be allocated appropriately to maximize the benefits to society. [ Read More ]

Value-Based Oncology: The Intersection of Drug Costs, Effectiveness, and Toxicity

William K. Fleming, PharmD; Bryan Loy, MD, MBA; Roy Beveridge, MD

July 2015, Vol 6, No 6 - VBCC Perspectives

Value-based oncology was one of the high-profile topics at the 2015 American Society of Clinical Oncology (ASCO) meeting. It is something that is discussed widely in print and on social media. It is certainly top of mind for payers, doctors, policymakers, business leaders, and, in particular, patients. [ Read More ]

ASCO’s Value Framework Abandons the Hippocratic Oath

Robert Goldberg, PhD

July 2015, Vol 6, No 6 - VBCC Perspectives

The American Society of Clinical Oncology (ASCO) new value framework abandons the Hippocratic Oath. No longer is the doctor’s first obligation to “apply, for the benefit of the sick, all measures which are required.” Instead, ASCO’s value framework has the potential to help insurers “evaluate the relative value of new treatments” as they develop “benefit structures, adjustment of insurance premiums, and implementation of clinical pathways and administrative controls." [ Read More ]

Considering Prophylactic Salpingo-Oophorectomy in Women with BRCA Mutations

Allison W. Kurian, MD, MSc; Jonathan S. Berek, MD, MMS

March 2014, Vol 5, No 2 - VBCC Perspectives

The study “Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation” that was recently published in the Journal of Clinical Oncology (Finch AP, et al. 2014 February 24 [Epub ahead of print]) provides an update of previous work by the same investigators on a similar population. [ Read More ]

Cancer Prehabilitation May Reduce Healthcare Costs and Improve Outcomes

Julie K. Silver, MD

October 2013, Vol 4, No 8 - VBCC Perspectives

Prehabilitation (or “prehab”) has a long history as an important part of the rehabilitation care continuum. For example, patients who are electing to have a total hip or knee arthroplasty may have preoperative assessments and interventions that are sometimes grouped together and called “joint camp.” Prehabilitation has also been gaining traction in the oncology community, because of the potential it may have to improve cancer care. [ Read More ]

The Importance of Prioritizing Palliative Care in Oncology: How Payers Can Assist Providers

Ellen Licking; John Whang, MD, FACC; Rhonda Greenapple, MSPH, Reimbursement Intelligence

February 2013, Vol 4, No 2 - VBCC Perspectives

Too often, palliative care, which was officially recognized as a medical specialty in 2006, is mistakenly thought to be synonymous with hospice care. Although palliative care includes the coordination of care for patients at the end of their lives, it more broadly aims to reduce patient suffering and is available to all patients with serious disease. It is designed to be given alongside active care, and certain chemotherapies have important palliative properties, including reduction in pain and nausea and improved quality of life (QOL) by the use of more tolerable dosing mechanisms.

[ Read More ]